Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215223 | 0.94 | ALDH1A1 (0.31) | LMNAALDH1A1 | |
| SCHEMBL10095223 | 0.79 | USP2 (0.38) | CYP1A2CYP3A4CYP2C19PLA2G2C | |
| SCHEMBL17807368 | 0.79 | HIF1A (0.38) | HIF1A | |
| SCHEMBL12586739 | 0.79 | USP2 (0.38) | CYP1A2CYP3A4CYP2C19PLA2G2C | |
| SCHEMBL10949893 | 0.79 | USP2 (0.38) | CYP1A2CYP3A4CYP2C19PLA2G2C | |
| SCHEMBL12232015 | 0.78 | LMNA (0.43) | LMNACYP1A2CYP3A4CYP2C19RARB | |
| SCHEMBL215747 | 0.78 | HIF1A (0.36) | LMNARARBALDH1A1HIF1AEPAS1 | |
| SCHEMBL10120811 | 0.76 | SPHK1 (0.44) | LMNACYP3A4RARBALDH1A1PLA2G2C | |
| SCHEMBL10119363 | 0.76 | SPHK1 (0.44) | LMNACYP3A4RARBALDH1A1PLA2G2C | |
| SCHEMBL7866199 | 0.76 | SPHK1 (0.44) | LMNACYP3A4RARBALDH1A1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| EP-2118249-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | Givaudan Nederland Services B.V. (NL) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008092678-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100132249-A1 | Fragrance Compositions and Compounds | H1-0, H1-10, H1-5 | LMNA 2425/4885CYP1A2 779/4885CYP3A4 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.